Treatment of estrogen receptor-positive breast cancer. Curr Med Chem 2013; 20: 596-604 [PMID: 23278394 DOI: 10.2174/0929867 13804999303]Lumachi F, Brunello A, Maruzzo M, Basso U, Basso SM. Treatment of estrogen receptor-positive breast cancer. Current medicinal chemistry. 2013;20(5):596-...
Calcitriol (1,25-dihydroxyvitamin D3), the hormonally active form of vitamin D, inhibits the growth of many malignant cells including breast cancer (BCa) c... AV Krishnan,S Swami,D Feldman - 《Steroids》 被引量: 99发表: 2012年 Current medical treatment of estrogen receptor-positive breast ...
We assess the issue in clinically relevant settings by a genetic approach and inject ER + breast cancer cell lines and patient-derived tumor cells to the milk ducts of immunocompromised mice. Such ER + xenografts were exposed to physiologically relevant levels of 17-β-estradiol (E2) ...
Here, we retrospectively evaluated the importance of HER4 expression on the outcome of tamoxifen- and aromatase inhibitor-treated estrogen receptor-positive breast cancer patients (n = 258). In addition, we experimentally analyzed the efficiency of tamoxifen treatment as a function of HER4 co-expr...
Investigational drugs shut down critical genes and cancer cells responsible for tumor growth. Investigational drugs shut down critical genes and cancer cells responsible for tumor growth. A new therapeutic approach for women with estrogen-receptor-positive breast cancer is showing positive result...
Objective To observe the therapeutic effect and toxicity of fulvestrant on estrogen receptor(ER)-positive advanced breast cancer.Methods Twenty-seven patients who received fulvestrant treatment in our hospital from August 2011 to May 2012 were enrolled in this study.Their clinical data including the dis...
- 《Breast Cancer Research & Treatment》 被引量: 0发表: 2018年 149POnly estrogen receptor "positive" is not enough to predict the prognosis of breast cancer running head: Revisiting estrogen positive tumors in 8th AJCC staging era Only estrogen receptor "positive" is not enough to predict the...
The nonsteroidal antiestrogen tamoxifen has emerged as a highly effective, nontoxic endocrine therapy for women with Stage IV and II estrogen receptor-positive breast cancer. Tamoxifen appears to act by blocking endogenous estrogen action at the target tissue level rather than by suppression of circula...
Estrogen receptor-positive (ER+) breast cancer (BCa) often recurs after long latency, and is known to favor bone as a metastatic site. We hypothesized that skeletal recurrence of ER+ BCa follows a different chronological pattern from that of nonskeletal recurrence. We retrospectively evaluated 434...
Unraveling the role of the ER pathway in resistance to HER2-directed agents could potentially result in therapeutic approaches that can improve outcome for patients with ER-positive, HER2-positive breast cancer. 展开 关键词: Estrogen receptor Human epidermal growth factor receptor (HER)2 Endocrine ...